ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early ...
FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...
ImmunityBio launched the ResQ215B Phase 2 trial of a chemotherapy free, outpatient immunotherapy regimen for indolent B cell non Hodgkin lymphoma. The trial combines CAR NK cell therapy with the ...
Multiple patients substantially exceed expected survival at low dose levels; absence of dose-limiting toxicities supports escalation to doses up to 100x higher Trial ...
Anixa Biosciences, Inc. ANIX on Monday provided an update on patient outcomes observed in its ongoing Phase 1 ovarian cancer CAR-T clinical trial, following regulatory approval of a protocol amendment ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 clinical study evaluating a novel chemotherapy-free and ...
CD19 CAR-NK cell therapy with rituximab achieved durable complete responses in Waldenström Non-Hodgkin lymphoma, with up to 15 months of remission. The QUILT-106 study reported 100% disease control ...
Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...
Early data of Waldenström’s non-Hodgkin lymphoma patients enrolled in a trial testing Immunitybio Inc.’s off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK), ...
NEW YORK – A gene therapy using lentiviral particles to generate CAR T cells inside multiple myeloma patients has shown the ability to eliminate the small number of cancer cells in bone marrow that ...
Promising advancements in CAR T-cell therapy for large B-cell lymphoma (LBCL) include potential new safety parameters, opportunities for precision care, and increased chances of achieving remission ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results